Abstract library

6 results for "Sizer".
#614 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors
Introduction: The diagnosis of neuroendocrine tumors (NET) is often delayed due to the vague symptoms and rareness of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Catharina M Korse
#1248 Case Report of Recurrent VIPoma
Introduction: 51yr presented with 7 month diarrhoea&2 stone weight loss. All tests negative, only abnormality hypokalaemia. FGH profile: VIP raised>400, peptide histidine methionine>1000, GAWK of 250. Diagnosis of VIPoma. CT: 5cm mass tail & body of pancreas, no hepatic or adrenal lesions. Octreotide treatment started. Bowel frequency improved, hypokalaemia corrected. Octreotide scan showed uptake only in pancreas. Patient readmitted 5 months later hypokalaemic myopathy, K 1.7, surgical distal pancreatectomy & splenectomy completed. Histology: NET within pancreas, moderate cellular differentiation, variable mitotic rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr Victoria Mulcahy
Keywords: VIPoma
#1738 Sinonasal Neuroendocrine Small Blue Cell Tumour (SNBCT) Presenting with Bone Marrow Failure – A Very Rare Diagnostic and Therapeutic Challenge
Introduction: A 75 year old female presented with rapid onset right neck swelling and nasal bleeding. CT showed an infiltrative soft tissue mass involving the entire right nasal cavity and a lymph node mass in the right neck.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Dr Simon Duke
Authors: Dawes A, Duke S, Tahir Q, Leitch J, ...
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S, ...
#1507 The CDK4/6 Inhibitor Palbociclib Induces Anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with heterogeneous molecular backgrounds and mostly unknown druggable driver mutations. Especially for the midgut NENs effective treatment options are limited. The retinoblastoma pathway is often inactive due to CDK4/6 overexpression in pancreatic NENs. Palbociclib is a FDA approved (ER-positive and HER2-negative breast cancer) cyclin-dependent kinases 4 and 6 inhibitor and might impair cell cycle progression and proliferation.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest